Arbeitsgruppe Verkehrsmedizin der Schweizerischen Gesellschaft für Rechtsmedizin (2008) Handbuch der verkehrsmedizinischen Begutachtung. Huber, Bern
Barbone F, McMahon A, Davey P et al (1998) Association of road-traffic accidents with benzodiazepine use. Lancet 352:1331–1336
CrossRefPubMedBattistella G, Fornari E, Thomas A et al (2013) Weed or wheel! FMRI, behavioural, and toxicological investigations of how cannabis smoking affects skills necessary for driving. PLoS One 8:e52545. doi:10.1371/journal.pone.0052545
CrossRefPubMedPubMedCentralBeblo T, Sinnamon G, Baune BT (2011) Specifying the neuropsychology of affective disorders: clinical, demographic and neurobiological factors. Neuropsychol Rev 21:337–359
CrossRefPubMedBech P, Thomsen J, Rafaelsen OJ (1976) Long-term lithium treatment: effects on simulated driving and other psychological tests. Eur J Clin Pharmacol 10:331–335
CrossRefPubMedBergeron J, Paquette M (2014) Relationships between frequency of driving under the influence of cannabis, self-reported reckless driving and risk-taking behavior observed in a driving simulator. J Safety Res 49:19–24
CrossRefPubMedBerghaus G (2002) Methadon-Substitution und Fahrsicherheit/Fahreignung – Überblick über die experimentellen Forschungsergebnisse. Suchtmed 4:169–174
Berghaus G, Brenner-Hartmann J (2012) Fahrsicherheit und Fahreignung – Determinanten der Verkehrssicherheit. In: Madea B, Musshoff F, Berghaus G (Hrsg) Verkehrsmedizin. Fahrsicherheit, Fahreignung, Unfallrekonstruktion. Deutscher Ärzte-Verlag, Köln
Bosanquet D, Macdougall HG, Rogers SJ et al (2013) Driving on ice: impaired driving skills in current methamphetamine users. Psychopharmacology (Berl) 225:162–171
CrossRefBramnes JG, Skurtveit S, Inke NC et al (2008) Minor increase in risk of road traffic accidents after prescription of antidepressants: a study of population registry data in Norway. J Clin Psychiatry 89:1099–1103
CrossRefBrown LB, Brian RO (2004) Driving and Dementia: a review of the literature. J Geriatr Psychiatry Neurol 17:232–240
CrossRefPubMedPubMedCentralBrunnauer A, Laux G (2003) Fahrtüchtigkeit und Antidepressiva. Psychiatr Prax 30(Suppl 2):102–105
PubMedBrunnauer A, Laux G (2006) Fahrtüchtigkeit, schizophrene Psychosen und Neuroleptika. In: Schmauss M (Hrsg) Schizophrene Psychosen, 2. Aufl. UNI-MED, Bremen, S 383–392
Brunnauer A, Laux G (2010) Psychopharmaka und Fahrtüchtigkeit. In: Riederer PF, Laux G (Hrsg) Grundlagen der Neuro-Psychopharmakologie. Ein Therapiehandbuch. Springer, Wien/New York, S 475–482
Brunnauer A, Laux G (2011) Psychische Erkrankungen, Psychopharmaka und Fahrtauglichkeit. In: Golka K, Hengstler JG, Letzel S, Nowak D (Hrsg) Verkehrsmedizin – arbeitsmedizinische Aspekte. Orientierungshilfe für Praxis, Klinik und Betrieb. Ecomed Medizin, Heidelberg, S 127–152
Brunnauer A, Laux G (2013) The effects of most commonly prescribed second generation antidepressants on driving ability: a systematic review. J Neural Transm 120:225–232
CrossRefPubMedBrunnauer A, Laux G, Geiger E, Möller HJ (2004) The impact of antipsychotics on psychomotor performance with regard to car driving skills. J Clin Psychopharmacol 24:155–160
CrossRefPubMedBrunnauer A, Geiger E, Laux G et al (2005) Fahrsimulation und psychomotorische Leistungsfähigkeit schizophrener Patienten unter Flupentixol, Risperidon und Haloperidol: Ergebnisse einer klinischen Untersuchung. Psychopharmakotherapie 12:91–96
Brunnauer A, Laux G, Geiger E et al (2006) Antidepressants and driving ability: results from a clinical study. J Clin Psychiatry 67:1776–1781
CrossRefPubMedBrunnauer A, Laux G, David I, Fric M et al (2008) The impact of reboxetine and mirtazapine on driving simulator performance and psychomotor function in depressed patients. J Clin Psychiatry 69:1880–1886
CrossRefPubMedBrunnauer A, Laux G, Zwick S (2009) Driving simulator performance and psychomotor functions of patients treated with antipsychotics. Eur Arch Psychiatry Clin Neurosci 259:483–489
CrossRefPubMedBrunnauer A, Buschert C, Laux G (2014) Demenz und Autofahren. Nervenarzt 85:811–815
CrossRefPubMedBrunnauer A, Buschert V, Fric M et al (2015) Driving performance and psychomotor function in depressed patients treated with agomelatine or venlafaxine. Pharmacopsychiatry 48:65–71
CrossRefPubMedByas-Smith MG, Chapman SL, Reed B, Cotsonis G (2005) The effects of opioids on driving and psychomotor performance in patients with chronic pain. Clin J Pain 21:345–352
CrossRefPubMedCox DJ, Davis M, Mikami AY et al (2012) Long-acting methylphenidate reduces collison rates of young adult drivers with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 32:225–230
CrossRefPubMedCurrie D, Hashemi K, Fothergill J et al (1995) The use of antidepressants and benzodiazepines in the perpetrators and victims of accident. Occup Med (Lond) 45:323–325
CrossRefDagtekin O, Gerbershagen HJ, Wagner W et al (2007) Assessing cognitive and psychomotor performance under long-term treatment with transdermal buprenorphine in chronic noncancer pain patients. Anesth Analog 105:1442–1448
CrossRefDassanayake T, Michie P, Carter G, Jones A (2011) Effects of benzodiazepines, antidepressants and opioids on driving: a systemic review and meta-analysis of epidemiological and experimental evidence. Drug Saf 34:125–156
CrossRefPubMedDe las Cuevas C, Ramallo Y, Sanz EJ (2010) Psychomotor performance and fitness to drive: the influence of psychiatric disease and its pharmacological treatment. Psychiatry Res 176:236–241
CrossRefPubMedDevlin A, McGillivray J, Charlton J et al (2012) Investigating driving behaviour of older drivers with mild cognitive impairment using a portable driving simulator. Accid Anal Prev 49:300–307
CrossRefPubMedDilling H, Mombour W, Schmidt MH (Hrsg) (2014) Internationale Klassifikation psychischer Störungen: ICD-10, Kapitel V (F); klinisch- diagnostische Leitlinien/Weltgesundheitsorganisation. Hans Huber, Göttingen
Dittert S, Naber D, Soyka M (1999) Methadonsubstitution und Fahrtauglichkeit. Nervenarzt 70:457–462
CrossRefPubMedDubinsky R, Stein A, Lyons K (2000) Practice parameters: risk of driving and Alzheimer‘s disease (an evidence-based review). Report of the quality standards subcommittee of the American Academy of Neurology. Neurology 54:2205–2211
CrossRefPubMedElvik R (2013) Risk of road accident associated with the use of drugs: a systematic review and meta-analysis of evidence from epidemiological studies. Accid Anal Prev 60:254–267
CrossRefPubMedErnst J, Krapp S, Schuster T et al (2010) Fahrtauglichkeit bei Patienten mit frontotemporaler Demenz und Alzheimer-Demenz. Nervenarzt 81:79–85
CrossRefPubMedFishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS (2002) Can patients taking opioids drive safely? A structured evidence-based review. J Pain Palliat Care Pharmacother 16:9–28
CrossRefPubMedFritelli C, Borghetti D, Iudice G et al (2009) Effects of Alzheimer’s disease and mild cognitive impairment on driving ability: a controlled clinical study by simulated driving test. Int J Geriatr Psychiatry 24:232–238
CrossRefGauthier S, Kraus S, Ajdacic-Gross V et al (2015) Suizide im Straßenverkehr in der Schweiz und in Bayern. In: Graw M, Dittmann V, Schubert W (Hrsg) Interdisziplinäre Unfallrekonstruktion und Prävention. Tagungsband 10. Gemeinsames Symposium der DGVM und DGVP am 05. Und 06. September 2014 in München. Kirschbaum Verlag, Bonn, S 74–76
Gibson JE, Hubbard RB, Smith CJ et al (2009) Use of self controlled analytical techniques to assess the association between use of prescription medications and the risk of motor vehicle crashes. Am J Epidemiol 169:761–768
CrossRefPubMedGolz D, Huchler S, Jörg A, Küst J (2004) Beurteilung der Fahreignung. Z Neuropsychol 15:157–167
CrossRefGrabe HJ, Wolf T, Grätz S, Laux G (1998) The influence of polypharmacological antidepressive treatment on central nervous information processing of depressed patients: implications for fitness to drive. Neuropsychobiology 37:200–204
CrossRefPubMedGrabe HJ, Wolf T, Grätz S, Laux G (1999) The influence of clozapine and typical neuroleptics on information processing of the central nervous system under clinical conditions in schizophrenic disorders: implications for fitness to drive. Neuropsychobiology 40:196–201
CrossRefPubMedGräcmann N, Albrecht M (2014) Begutachtungsleitlinien zur Kraftfahreignung. Bundesanstalt für Straßenwesen. Berichte der Bundesanstalt für Straßenwesen. Mensch und Sicherheit. M115. Bergisch Gladbach
Hart CL, Marvin CB, Silver R et al (2012) Is cognitive functioning impaired in methamphetamine users? A critical review. Neuropsychoparmacology 37:586–608
CrossRefHartmann RL, Huestis MA (2013) Cannabis effects on driving skills. Clin Chem 59:478–492
CrossRefHatcher S, Sims R, Thompson D (1990) The effects of chronic lithium treatment on psychomotor performance related to driving. Br J Psychiatry 157:275–278
CrossRefPubMedHauri-Bionda R, Bar W, Friedrich-Koch A (1998) Driving fitness/driving capacity of patients treated with methadon. Schweiz Med Wochenschr 10:1538–1547
Heinrichs RW, Zakzanis KK (1998) Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 12:426–445
CrossRefPubMedHemmelgarn B, Suissa S, Huang A et al (1997) Benzodiazepine use and the risk of motor vehicle crash in the elderly. JAMA 278:27–31
CrossRefPubMedHopkins RW, Kilik L, Day DJA et al (2004) Driving and dementia in Ontario: a quantitative assessment of the problem. Can J Psychiatry 49:434–438
PubMedHughes CP, Berg L, Danziger WL et al (1982) A new clinical scale for the staging of dementia. Br J Psychiatry 140:566–572
CrossRefPubMedKagerer S, Winter C, Möller HJ, Soyka M (2003) Effects of haloperidol and atypical neuroleptics on psychomotor performance and driving ability in schizophrenic patients. Results from an experimental study. Neuropsychobiology 47:212–218
CrossRefPubMedKannheiser W (2000) Mögliche verkehrsrelevante Auswirkungen von gewohnheitsmäßigem Cannabiskonsum. N Zschr Verkehrsrecht 13:57–104
Kawano N, Iwamoto K, Iidaka T, Ozaki N (2012) Effects of mild cognitive impairment on driving performance in older drivers. J Am Geriatr Soc 60:1379–1381
CrossRefPubMedKlebelsberg D (1982) Verkehrspsychologie. Springer, Berlin
CrossRefKopelmann MD (1995) The Korsakow-Syndrome. Br J Psychiatry 166:154–173
CrossRefKress HG, Kraft B (2005) Opioid medication and driving ability. Eur J Pain 9:141–144
CrossRefPubMedLaux G (1995) Aktueller Stand der behandlung mit Benzodiazepinen. Nervenarzt 66:311–322
Lakemeyer M (1998) Opiathaltige Schmerzmittel und Verkehrssicherheit. Berichte der Bundesanstalt für Straßenwesen, Mensch und Sicherheit M 86. Bergisch Gladbach
Laux G (2002) Psychische Störungen und Fahrtauglichkeit. Eine Übersicht. Nervenarzt 73:231–238
CrossRefPubMedLaux G, Brunnauer A (2014) Fahrtauglichkeit bei affektiven Störungen und unter Psychopharmaka. Nervenarzt 85:822–828
CrossRefPubMedLaux G, Brunnauer A (2015) Fahrtauglichkeit unter Antidepressiva. Ein Update unter Berücksichtigung des neuen Antidepressivums Vortioxetin. Psychopharmakotherapie 22:35–41
LeRoy AA, Morse ML (2008) Mutltiple medications and vehicle crashes: analysis of databases (Report No. DOT Hs 810 858) US Department of Transportation National Highway Traffic Safety Transportation.
www.nhtsa.gov/DOT/NHTSA/…/Articles/…/810858.pdf. Zugegriffen am 20.06.2015
Leveille SG, Buchner DM, Koepsell TD et al (1994) Psychoactive medications and injurious motor vehicle collisions involving older drivers. Epidemiology 5:591–598
CrossRefPubMedLewrenz H (2000) Begutachtungs-Leitlinien zur Kraftfahrereignung. Wirtschaftsverlag, Bremerhaven
Menendez A (1994) Psychiatric illness and driving performance. J Traffic Med 22:145–152
Millan MJ, Agid Y, Brüne M et al (2012) Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov 11:141–168
CrossRefPubMed(Muster)Berufsordnung für die in Deutschland tätigen Ärztinnen und Ärzte – MBO-Ä – 1997 – in der Fassung der Beschlüsse des 114. Deutschen Ärztetages 2011 in Kiel (2011) Dtsch Ärztebl 108: A1980-A1992
O’Hanlon J, Vermeeren A, Uiterwijk M et al (1995) Anxiolytics’ effects on the actual driving performance of patients and healthy volunteers in a standardized test. An Integration of three studies. Neuropsychology 31:81–88
Okonkwo OC, Griffith HR, Vance DE et al (2009) Awareness of functional difficulties in mild cognitive impairment: a multidomain Assessment approach. J Am Geriatr Soc 57:978–984
CrossRefPubMedPubMedCentralPanenka WJ, Procyshyn RM, Lecomte T et al (2013) Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings. Drug Alcohol Depend 129:167–179
CrossRefPubMedPoschadel S, Falkenstein M, Pappachan P, Poll E et al (2009) Testverfahren zur psychometrischen Leistungsprüfung der Fahreignung. Berichte der Bundesanstalt für Straßenwesen. Mensch und Sicherheit, M203
Ramaekers JG (2003) Antidepressants and driver impairment : emprirical evidence from a standard on-the-road test. J Clin Psychiatry 64:20–29
CrossRefPubMedRamaekers JG, Kuypers HP, Bosker WM et al (2012) Effects of stimulant drugs on actual and simulated driving: perspectives from four experimental studies conducted as part of the DRUID research consortium. Psychopharmacology 222:413–418
Rapoport MJ (2011) At-fault motor vehicle crash risk in elderly patients treated with antidepressants. Am J Geriatr Psychiatry 19:998–1006
CrossRefPubMedRavera S, van Rein N, de Gier J et al (2011) Road traffic accidents and psychotropic medication use in the Netherlands: a case–control study. Br J Clin Pharmacol 72:505–515
CrossRefPubMedPubMedCentralRay W, Fought R, Decker M (1992) Psychoactive drugs and the risk of injurious motor vehicle crashes in elderly drivers. Am J Epidemiol 136:873–883
CrossRefPubMedSabatowski R, Berghaus G, Strumpf M, Radbruch L (2003) Opioide und Fahrsicherheit – ein unlösbares Problem? Dtsch Med Wochenschr 128:337–341
CrossRefPubMedSchubert W, Schneider W, Eisenmenger W, Stephan E (2005) Begutachtungs-Leitlinien zur Kraftfahrereignung. Kommentar. Kirschbaum Verlag, Bonn
Schubert W, Dittman V, Brenner-Hartmann J (2013) Urteilsbildung in der Fahreignungsbegutachtung. Beurteilungskriterien. Kirschbaum Verlag, Bonn
Schulz E, Vollrath M, Klimesch C, Szegedi A (1997) Fahruntüchtigkeit durch Cannabis, Amphetamine und Kokain. Berichte der Bundesanstalt für Straßenwesen, Mensch und Sicherheit M 81, Bergisch Gladbach
Segmiller FM, Hermisson I, Riedel M et al (2013) Driving ability according to German guidelines in stabilized bipolar I and II outpatients receiving lithium or lamotrigine. J Clin Pharmacol 53:459–462
CrossRefPubMedSilverstone T (1988) The influence of psychiatric disease and its treatment on driving performance. Psychopharmacology (Berl) 3:59–66
Smink BE, Egberts AC, Lusthof KJ et al (2010) The relationship between benzodiazepine use and traffic accidents: a systematic literature review. CNS Drugs 24:639–653
CrossRefPubMedSobanski E, Sabilic D, Alm B et al (2008) Driving-related risks and impact of methylphenidate treatment on driving in adults with attention-deficit/hyperactivity disorder (ADHD). J Neural Transm 115:347–356
CrossRefPubMedSobanski E, Sabilic D, Alm B et al (2013) Driving performance in adults with ADHD: results from a randomized, waiting list controlled trial with atomoxetine. Eur Psychiatry 28:379–385
CrossRefPubMedSoyka M, Winter C, Kagerer S et al (2005a) Effects of haloperidol and risperidone on psychomotor performance relevant to driving ability in schizophrenic patients compared to healthy controls. J Psychiatry Res 33:101–108
CrossRefSoyka M, Hock B, Kagerer S et al (2005b) Less impairment on one portion of a driving-relevant psychomotor battery in Buprenorphine-maintained than in Methadone-maintained patients: results of a randomized clinical trial. J Clin Psychopharmacol 25:490–493
CrossRefPubMedSoyka M (2014) Opioids and traffic safety - focus on buprenorphine. Pharmacopsychiatry 47:7–17
Soyka M, Dittert S, Kagerer-Volk S, Soyka M (2014) Fahrtauglichkeit bei Abhängigkeitserkrankungen und Schizophrenie. Nervenarzt 85:816–821
CrossRefPubMedSpecka M, Finkbeiner T (2000) Methadonsubstitution und Fahrtauglichkeit. In: Krüger HP (Hrsg) Drogen im Straßenverkehr – ein Problem aus europäischer Perspektive. Lambertus, Freiburg i. Br, S 99–109
Stevens A, Foerster K (2001) Die neuen Begutachtungs-Leitlinien zur Kraftfahrereignung. Erfahrungsbericht und kritische Besprechung. Spektrum 6:125–130
Strumpf M, Willweber-Strumpf A, Herberg KW, Zenz M (2005) Safety-relevant performance of patients on chronic opioid therapy. Schmerz 19:426–433
CrossRefPubMedTsuang MT, Boor M, Fleming JA (1985) Psychiatric aspects of traffic accidents. Am J Psychiatry 142:538–546
CrossRefPubMedTurk K, Dugan E (2014) Research Brief: a literature review of frontotemporal dementia and driving. Am J Alzheimers Dis Other Demen 29: 404–408
Uc EY, Rizzo M, Anderson SW et al (2004) Driver route-following and safety errors in early Alheimer’s disease. Neurology 63:832–837
CrossRefPubMedVaa T (2003) Impairments, diseases, age and their relative risks of accident involvement: results from a meta analysis. IMMORTAL EU research project Deliverable R1.1.
www.immortal.or.at
Vainio A, Ollila J, Matikainen E et al (1995) Driving ability in cancer patients receiving long-term morphine analgesia. Lancet 346:667–670
CrossRefPubMedVan Laar M, Volkerts E (1998) Driving and benzodiazepine use. Evidence that they do not mix. CNS Drugs 10:383–396
CrossRefVerster JC, Volkerts ER (2004) Antihistamines and driving ability: evidence from on-the road driving studies during normal traffic. Ann Allergy Asthma Immunol 92:294–304
CrossRefPubMedVerster JC, Volkerts ER, Schreuder AH et al (2002) Residual effects of middle-of the night administration of zaleplon and zolpidem on driving ability, memory functions, and psychomotor performance. J Clin Psychopharmacol 22:576–583
CrossRefPubMedVerster JC, Veldhuijzen DS, Volkerts RE (2004) Residual effect of sleep medication on driving ability. Sleep Med Rev 8:309–325
CrossRefPubMedWingo AP, Wingo TS, Harvey PD et al (2009) Effects of lithium on cognitive performance: a meta-analysis. J Clin Psychiatry 70:1588–1597
CrossRefPubMedWood S, Sage JR, Shuman T et al (2013) Psychostimulants and cognition: a continuum of behavioral and cognitive activation. Parmacol Rev 66(19):193–221